文献速递炎症性肠病

维得利珠单抗谷浓度与炎症性肠病临床及内镜结局:系统综述与荟萃分析

Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-18

UC内镜缓解与较高谷浓度强相关(MD 4.86 μg/mL),UC和CD临床缓解亦相关但异质性显著,CD内镜缓解无关联。汇总的缓解相关浓度支持UC维持目标≥13-15 μg/mL、CD≥10-12 μg/mL,但因多为横断面关联,不能推荐主动治疗药物监测。

要点

  • UC内镜缓解与较高维得利珠单抗谷浓度强相关,异质性低。
  • UC和CD临床缓解与较高谷浓度相关,但统计异质性显著。
  • CD内镜缓解与谷浓度无显著关联,需前瞻性干预试验验证。

核心结论

  • 较高维得利珠单抗谷浓度与缓解相关,以UC内镜缓解最为稳健。
  • 因关联多为横断面设计,可能反映反向因果而非剂量反应关系。
  • 推荐主动治疗药物监测前需前瞻性干预试验验证。

研究设计与样本

  • 遵循PRISMA 2020的系统综述与荟萃分析,检索建库至2026年4月文献。
  • 其中18项研究贡献定量合成,采用随机效应模型和限制性最大似然估计,用I2统计量量化异质性。

主要发现

  • UC内镜缓解与较高谷浓度强相关:MD 4.86 μg/mL(95%CI 2.75-6.98;P < .0001;I2 = 0.0%)。
  • UC临床缓解与较高谷浓度相关:MD 3.18 μg/mL(P = .025),但估计存在统计异质性。
  • CD临床缓解与较高谷浓度相关:MD 3.08 μg/mL(P < .0001),但估计存在统计异质性。
  • CD内镜缓解与谷浓度无显著关联:MD 1.40 μg/mL(P = .453)。

关键数值与推荐

  • 汇总的缓解相关浓度以描述性方式呈现,支持UC维持目标≥13-15 μg/mL。
  • 汇总的缓解相关浓度以描述性方式呈现,支持CD维持目标≥10-12 μg/mL。

临床怎么用

  • 临床可参考UC维持谷浓度≥13-15 μg/mL、CD≥10-12 μg/mL的汇总描述性目标。
  • 因证据以横断面关联为主,不应据此常规开展主动治疗药物监测。
  • 对UC内镜缓解的浓度-结局关联证据最强,可优先关注UC患者谷浓度。

局限性

  • 关联多为横断面设计,可能反映反向因果而非剂量反应关系。
  • 临床缓解估计存在统计异质性。
  • 需前瞻性干预试验方可推荐主动治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The role of therapeutic drug monitoring in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ trough concentrations with clinical (CR) and endoscopic remission (ER). METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched the literature from inception to April 2026 for studies reporting VDZ trough concentrations stratified by remission status in CD and UC. Outcomes were CR and ER. Pooled mean differences (MDs) were estimated using random-effects models with restricted maximum likelihood estimation; heterogeneity was quantified using the I2 statistic. RESULTS: Twenty-three studies (6753 patients) met inclusion criteria; 18 contributed to quantitative synthesis. Higher VDZ trough concentrations were strongly associated with ER in UC (MD, 4.86 μg/mL; 95% confidence interval, 2.75-6.98; P < .0001; I2 = 0.0%). Higher concentrations were also associated with CR in UC (MD, 3.18 μg/mL; P = .025) and CD (MD, 3.08 μg/mL; P < .0001), although these clinical remission estimates were statistically heterogeneous; no association was observed for ER in CD (MD, 1.40 μg/mL; P = .453). Pooled remission-associated concentrations were presented descriptively and supported maintenance targets of ≥13 to 15 μg/mL in UC and ≥10 to 12 μg/mL in CD. CONCLUSIONS: Higher VDZ trough concentrations were associated with remission, most robustly for ER in UC. As these associations are largely cross-sectional, they may reflect reverse causation rather than a dose-response relationship. Prospective interventional trials are required before proactive therapeutic drug monitoring can be recommended.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Soliman MA, Saraga A, Gade A, et al. Vedolizumab Trough Concentrations and Clinical and Endoscopic Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42759685. doi:10.1016/j.cgh.2026.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。